Sonova SOON.SW drops 4.03% to CHF171.30 on 24 Mar 2026: market closed, outlook

The SOON.SW stock closed the SIX session down 4.03%, falling to CHF171.30 on 24 Mar 2026 as volume spiked to 214,893.00 shares. Investors pushed the medical device leader lower after a sustained multi-month slide; today’s move left Sonova Holding AG (SOON.SW) trading well below its 50-day average of CHF202.90 and 200-day average of CHF217.58. We examine valuation, technical signals, Meyka grade and the forecasts that frame whether this decline is a buying window or a warning for Switzerland-listed shareholders.

SOON.SW stock: today’s move and immediate drivers

Sonova Holding AG (SOON.SW) closed on the SIX in Switzerland at CHF171.30, down CHF7.20 or 4.03%, with a day low of CHF168.00 and high of CHF172.95. Trading volume was 214,893.00, above the average of 170,120.00, indicating heavier selling pressure. The one-day drop extended the YTD decline to -19.32% and the 3-month slide to -18.34%.

Market context: headphones and hearing-device peers have mixed results this week, and healthcare sector weakness (average PE 29.67) weighed on Sonova’s multiple compression today.

SOON.SW stock: valuation and financials

Sonova trades at PE 19.29 on reported EPS 8.71, below the healthcare sector average PE 29.67, suggesting relative valuation support. Key ratios: price-to-sales 2.60, price-to-book 4.13, and dividend yield roughly 2.62% with a dividend per share of 4.40 CHF. Market cap stands near CHF10,017,570,909.00 with 59,610,657.00 shares outstanding.

Margins and cash: Sonova shows a gross margin above 70.55% and operating margin near 18.23%, while free cash flow yield is 7.12%. Debt metrics are moderate with debt-to-equity 0.76 and interest coverage 20.51, but intangible assets remain high.

SOON.SW stock: technical picture and market signals

Technically SOON.SW is oversold: RSI 23.69 and Stochastic %K 6.09. MACD is negative with histogram -2.13, and ADX 31.50 signals a strong downward trend. Bollinger bands show the lower band at CHF174.16, which the price pierced intraday.

These signals show momentum is to the downside, but oversold indicators can precede short-term bounces. Traders should weigh volatile ATR 6.66 and on-balance volume that points to net outflows.

Meyka AI rates SOON.SW with a score out of 100

Meyka AI rates SOON.SW with a score out of 100: 79.31 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model highlights strong ROE and ROA but flags leverage and valuation headwinds.

These grades are not guaranteed and we are not financial advisors. For deeper detail, see the company profile and metrics on the Meyka platform.

SOON.SW stock: risks, catalysts and sector context

Key risks include slower global hearing-device demand, margin pressure from price competition, and high intangible asset exposure. Sonova’s debt-to-equity of 0.76 and net debt-to-EBITDA near 1.52 mean leverage is manageable but not trivial.

Catalysts: next earnings announcement on 18 May 2026 could reset sentiment if revenue and margin guidance beat expectations. Sector context: healthcare peers trade at higher multiples, which could re-rate Sonova if it shows sustainable growth. For peer moves, see coverage on Alcon and Straumann for sector trends Investing – Alcon and Investing – Straumann.

SOON.SW stock: forecast, price target and practical trading notes

Meyka AI’s forecast model projects a short-term monthly price of CHF152.92 and a 12-month target of CHF207.07. Versus the current price CHF171.30, the monthly projection implies downside -10.73%, while the 12-month projection implies upside +20.90%. Forecasts are model-based projections and not guarantees.

Practical notes: conservative investors may wait for a confirmed reversal above the 50-day average CHF202.90. Active traders could watch oversold bounce levels near CHF168.00 and stops below the 52-week low CHF163.00. For quick reference see the Meyka stock page for SOON.SW.

Final Thoughts

Sonova Holding AG (SOON.SW) finished the SIX session on 24 Mar 2026 at CHF171.30, down 4.03% on above-average volume. Fundamentals still show a profitable medical-device business with EPS 8.71, PE 19.29, and free cash flow yield 7.12%, but the stock trades well below its 50-day and 200-day averages. Technical indicators point to oversold conditions, with RSI 23.69 and MACD negative, implying short-term risk but potential for mean reversion.

Meyka AI’s forecast model projects a 12-month level near CHF207.07, implying a modeled upside of about 20.90% from today’s price, while the one-month projection at CHF152.92 implies a near-term downside of -10.73%. That spread highlights the short-term volatility versus longer-term recovery scenario. Investors should weigh Sonova’s B+ Meyka grade and sector positioning against the company’s operating trends and upcoming earnings on 18 May 2026. Use disciplined sizing and clear stop rules if trading the move; long-term investors should watch guidance and margin trends before adding materially.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.